JPMorgan Chase & Co. Has $7.06 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

JPMorgan Chase & Co. increased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 244.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 274,693 shares of the company’s stock after buying an additional 194,913 shares during the period. JPMorgan Chase & Co. owned 0.32% of IDEAYA Biosciences worth $7,060,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. R Squared Ltd bought a new stake in IDEAYA Biosciences in the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. increased its stake in shares of IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after acquiring an additional 853 shares in the last quarter. KBC Group NV lifted its position in shares of IDEAYA Biosciences by 84.6% during the 4th quarter. KBC Group NV now owns 4,197 shares of the company’s stock valued at $108,000 after acquiring an additional 1,923 shares during the period. Cibc World Markets Corp bought a new position in IDEAYA Biosciences during the fourth quarter worth $203,000. Finally, XTX Topco Ltd acquired a new stake in IDEAYA Biosciences in the third quarter worth $245,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on IDYA shares. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Finally, Stephens reiterated an “overweight” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Price Performance

IDYA opened at $16.18 on Thursday. The firm’s fifty day moving average price is $18.42 and its two-hundred day moving average price is $24.05. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -4.90 and a beta of 0.51. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. As a group, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.